J
Jorge Chaves
Publications - 20
Citations - 587
Jorge Chaves is an academic researcher. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 9, co-authored 20 publications receiving 368 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L. Disis,Mary L. Disis,Matthew H. Taylor,Karen Kelly,J. Thaddeus Beck,Michael S. Gordon,Kathleen M. Moore,Manish R. Patel,Jorge Chaves,Haeseong Park,Alain C. Mita,Erika Hamilton,Christina M. Annunziata,Hans Juergen Grote,Anja von Heydebreck,Jaspreet Grewal,Jaspreet Grewal,Vikram Chand,Vikram Chand,James L. Gulley +19 more
TL;DR: Avelumab demonstrated antitumor activity and acceptable safety in heavily pretreated patients with recurrent or refractory ovarian cancer in an expansion cohort of a phase 1b, open-label study.
Journal ArticleDOI
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Manish A. Shah,Alexander Starodub,Sunil Sharma,Jordan Berlin,Manish R. Patel,Zev A. Wainberg,Jorge Chaves,Michael S. Gordon,Kevin S Windsor,Carrie Baker Brachmann,Xi Huang,Gregory S. Vosganian,Julia D. Maltzman,Victoria Smith,Jeffrey A. Silverman,Heinz-Josef Lenz,Johanna C. Bendell +16 more
TL;DR: Andecaliximab monotherapy demonstrated no dose-limiting toxicity (DLT) in any cohort, displaying target-mediated drug disposition at the lowest dose (200 mg) and linear pharmacokinetics at higher doses.
Journal ArticleDOI
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Ulka N. Vaishampayan,Patrick Schöffski,Alain Ravaud,Christian Borel,Julio Peguero,Jorge Chaves,John C. Morris,Nuria Kotecki,Martin Smakal,Dongli Zhou,Silke Guenther,Marcis Bajars,James L. Gulley +12 more
TL;DR: Avelumab showed clinical activity and a manageable safety profile in both the 1’L and 2 L treatment setting in patients with mRCC, and these data support the use of avelumAB in combination with other agents in mR CC.
Journal ArticleDOI
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
Funda Meric-Bernstam,Diana L. Hanna,Anthony B. El-Khoueiry,Yoon-Koo Kang,Do-Youn Oh,Jorge Chaves,Sun Young Rha,Erika Hamilton,Shubham Pant,Milind Javle,Kanwal Pratap Singh Raghav,Allison Fortenberry,Todd E. Gray,Joseph Woolery,Keun Wook Lee +14 more
TL;DR: This data indicates that conventional second line chemotherapy for patients with unresectable, locally advanced or metastatic BTCs progressing after first line treatment with standard second line treatment yields £1.299 per treatment session.
Journal ArticleDOI
Phosphodiesterase 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells
TL;DR: The results suggest that as a result of their unusual sensitivity to PDE4 inhibitor–mediated up-regulation of GRα expression, treatment of B-CLL patients with combined PDE 4 inhibitor/glucocorticoid therapy may be of therapeutic benefit in this disease.